Reduction of plasma levels of betathromboglobulin and platelet factor 4 during hemodialysis: a possible role for a short acting inhibitor of platelet aggregation.
Plasma levels of the platelet markers betathromboglobulin and platelet factor 4 are elevated in patients with chronic renal failure, and their levels in hemodialysis patients increase further during exposure to the dialysis membrane. The effectiveness of a short acting inhibitor of platelet aggregation in reducing the blood levels of betathromboglobulin and platelet factor 4 was assessed by means of a double blind cross over study. A statistically significant reduction of betathromboglobulin and platelet factor 4 levels was observed during treatment with the platelet inhibitor.
D000328:Adult; D001609:Beta-Globulins / Q000032:analysis*; D001779:Blood Coagulation Factors / Q000032:analysis*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D054833:Isoindoles; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010654:Phenylbutyrates / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects*; D010978:Platelet Factor 4 / Q000032:analysis*; D006435:Renal Dialysis; D001620:beta-Thromboglobulin / Q000032:analysis*
D001609:Beta-Globulins; D001779:Blood Coagulation Factors; D054833:Isoindoles; D010654:Phenylbutyrates; D001620:beta-Thromboglobulin; D010978:Platelet Factor 4; C020371:indobufen